APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
27/07/2026
Voltar para busca
Dado oficial do USPTO
ASCENTAGE PHARMA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
ASCENTAGE PHARMA
ST13
US500000079246610Classe
5
Pedido
79246610
Registro
5876589
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
40
Atualização mais recente
09/08/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
10/08/2018
Data de registro
08/10/2019
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
08/10/2019
Última transação
09/08/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
98
Localização do titular
CN
Examinador
ENGEL, MICHAEL
Unidade examinadora
L70
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
ASCENTAGE PHARMA (SUZHOU) CO., LTD.
Jiangsu Ascentage Pharma Inc.
JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC.
Representantes
Kathryn E. Smith Wood Herron & Evans LLP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Medicines for the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; bacterial poisons; pharmaceutical preparations for the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; chemico-pharmaceutical preparations for the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; drugs for medical purposes in the nature of prescription apoptosis targeted compoundsnext-generation kinase inhibitors and senolytic drugs; drugs for the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; biological preparations for the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; chemical preparations for pharmaceutical or medical purposesfor use in the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease ; medicines for dental purposes; antibiotics; pharmaceutical preparations in the form of injection for the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; pharmaceutical preparations in the form of tablet for the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; active pharmaceutical ingredients in the nature of drug delivery agents in the form of powdersliquidscapsules that provide controlled release of active ingredients for a wide variety of pharmaceuticals; active chemical ingredients for use in the manufacture of pharmaceuticals for treating cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; active pharmaceutical ingredients for the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; biochemical medicines for the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; antiseptics; collyrium; suppositories; medicinal oils; transdermal patches for use in the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; candymedicated; candy for medical purposes; dietetic foods adapted for medical purposes; dietetic beverages adapted for medical purposes; dietetic substances adapted for medical use; mineral food supplements; nutritional supplements
Publicações
Histórico de despachos e eventos da marca no USPTO.
40 publicações encontradas
NREP
NEW REPRESENTATIVE AT IB RECEIVED
23/04/2026
ES71
TEAS SECTION 71 RECEIVED
07/04/2026
CHLD
CHANGE OF OWNER RECEIVED FROM IB
07/11/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
21/08/2025
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
21/08/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
21/08/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
21/08/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
21/08/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
21/08/2025
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
08/10/2024
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
01/04/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/04/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/04/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/04/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
01/04/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
01/04/2024
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
27/03/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
25/12/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
13/03/2020
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
03/02/2020
XXCR
GENERIC MADRID TRANSACTION CREATED
03/02/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
08/01/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
08/10/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
23/07/2019
PUBO
PUBLISHED FOR OPPOSITION
23/07/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/07/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
14/06/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
13/06/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/06/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/06/2019
RFNT
REFUSAL PROCESSED BY IB
11/01/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
21/12/2018
RFRR
REFUSAL PROCESSED BY MPU
20/12/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
11/12/2018
CNRT
NON-FINAL ACTION WRITTEN
10/12/2018
MAFR
APPLICATION FILING RECEIPT MAILED
04/12/2018
DOCK
ASSIGNED TO EXAMINER
30/11/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
30/11/2018
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
29/11/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ASCENTAGE PHARMA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.